Health Discovery Corporation Files Infringement Suit Against Intel Corporation
ATLANTA, Georgia, July 23, 2020 – Health Discovery Corporation (“Health Discovery”, “HDC” or the “Company”), an intellectual property development company with an intellectual property portfolio using patent protected advanced mathematical techniques, announced today that it has filed an infringement lawsuit against Intel Corporation (“Intel”) (NASDAQ: INTC). This infringement suit pertains to Health Discovery’s Support Vector Machine-Recursive Feature Elimination methods (“SVM-RFE”) patents.
On February 27, 2019, the United States Patent and Trademark Office (“USPTO”) ruled in favor of Health Discovery on the SVM-RFE Patents in the Interference proceeding between HDC and Intel. The Patent Trial and Appeal Board (“PTAB”) of the USPTO issued its decision, finding that Health Discovery is entitled to claim exclusive rights to the SVM-RFE technology as set forth in the patent application that was filed to provoke the Interference. The decision ordered Intel’s Patent No. 7,685,077 to be cancelled. The decision also dismissed Intel’s motions challenging the validity of Health Discovery’s pending claims and issued patents covering SVM-RFE.
In September 2019, the USPTO issued U.S. Patent No. 10,402,685 (“SVM-RFE Patent”) for Health Discovery’s patent application covering SVM-RFE. Health Discovery now owns four patents in the United States, owns five international patents covering the SVM-RFE method, and is the sole owner of all patents related to SVM-RFE. Furthermore, the USPTO granted a Patent Term Adjustment (“PTA”) to the SVM-RFE Patent. The PTA is 1,785 days (almost 5 years), which, added to the normal 20-year-from-filing patent term, extends this patent term to June 7, 2025.
As a result of the issuance of the SVM-RFE Patent, Health Discovery now has the right to exclude others from developing, commercializing or licensing this patented technology without the uncertainty of the Interference or concerns over the ownership of the SVM-RFE patents.
Health Discovery has attempted numerous times to avoid litigation with Intel regarding this dispute. Unfortunately, those efforts were unsuccessful and as a result this infringement suit is necessary. George H. McGovern, III, HDC’s Chairman and CEO, noted, “Health Discovery is taking the necessary steps to protect its sole ownership of SVM-RFE patents against infringement.”
Health Discovery has retained the firm of Dunlap, Bennett & Ludwig to represent the Company in this matter. In addition, HDC’s patent counsel is Musick Davidson LLP. The lawsuit has been filed in the United States District Court for the Western District of Texas, Waco Division where Intel has operations.
The continued focus on protecting Health Discovery’s patent portfolio remains a cornerstone of HDC’s commitment to work on behalf of all Health Discovery shareholders
https://www.sec.gov/Archives/edgar/data/11417...3d1_8k.htm
ATLANTA, Georgia, July 23, 2020 – Health Discovery Corporation (“Health Discovery”, “HDC” or the “Company”), an intellectual property development company with an intellectual property portfolio using patent protected advanced mathematical techniques, announced today that it has filed an infringement lawsuit against Intel Corporation (“Intel”) (NASDAQ: INTC). This infringement suit pertains to Health Discovery’s Support Vector Machine-Recursive Feature Elimination methods (“SVM-RFE”) patents.
On February 27, 2019, the United States Patent and Trademark Office (“USPTO”) ruled in favor of Health Discovery on the SVM-RFE Patents in the Interference proceeding between HDC and Intel. The Patent Trial and Appeal Board (“PTAB”) of the USPTO issued its decision, finding that Health Discovery is entitled to claim exclusive rights to the SVM-RFE technology as set forth in the patent application that was filed to provoke the Interference. The decision ordered Intel’s Patent No. 7,685,077 to be cancelled. The decision also dismissed Intel’s motions challenging the validity of Health Discovery’s pending claims and issued patents covering SVM-RFE.
In September 2019, the USPTO issued U.S. Patent No. 10,402,685 (“SVM-RFE Patent”) for Health Discovery’s patent application covering SVM-RFE. Health Discovery now owns four patents in the United States, owns five international patents covering the SVM-RFE method, and is the sole owner of all patents related to SVM-RFE. Furthermore, the USPTO granted a Patent Term Adjustment (“PTA”) to the SVM-RFE Patent. The PTA is 1,785 days (almost 5 years), which, added to the normal 20-year-from-filing patent term, extends this patent term to June 7, 2025.
As a result of the issuance of the SVM-RFE Patent, Health Discovery now has the right to exclude others from developing, commercializing or licensing this patented technology without the uncertainty of the Interference or concerns over the ownership of the SVM-RFE patents.
Health Discovery has attempted numerous times to avoid litigation with Intel regarding this dispute. Unfortunately, those efforts were unsuccessful and as a result this infringement suit is necessary. George H. McGovern, III, HDC’s Chairman and CEO, noted, “Health Discovery is taking the necessary steps to protect its sole ownership of SVM-RFE patents against infringement.”
Health Discovery has retained the firm of Dunlap, Bennett & Ludwig to represent the Company in this matter. In addition, HDC’s patent counsel is Musick Davidson LLP. The lawsuit has been filed in the United States District Court for the Western District of Texas, Waco Division where Intel has operations.
The continued focus on protecting Health Discovery’s patent portfolio remains a cornerstone of HDC’s commitment to work on behalf of all Health Discovery shareholders
https://www.sec.gov/Archives/edgar/data/11417...3d1_8k.htm
